Literature DB >> 11377170

Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones.

C E Stephens1, T M Felder, J W Sowell, G Andrei, J Balzarini, R Snoeck, E De Clercq.   

Abstract

Based on general SARs previously described for anti-HIV-1 diarylsulfone derivatives, a series of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes has been prepared and evaluated as potential antiviral and antitumor agents. In cell culture, some of the 2-aminothiophenes exhibited moderate and selective activity against HIV-1, with 2-amino-3-(2-nitrophenylsulfonyl)thiophene (7e) being most attractive (EC(50)=3.8 microg/mL, CC(50)=>100 microg/mL). In broad-spectrum antiviral assays, the 3-arylsulfonyl-2-(trifluoroacetamido)thiophenes (8c-g) and 2-acetamido-3-arylsulfonyl-5-nitrothiophenes (9f-g) proved considerably active (IC(50)=0.1-10 microg/mL) against human cytomegalovirus (CMV) and/or varicella zoster virus (VZV). Based on the activity of the trifluoroacetamides, ring-modified furan, N-(substituted)pyrrole, phenyl, and 3,4-thiophene analogues were prepared, and these compounds were also active against CMV and/or VZV, with the notable exception of the 3,4-thiophene derivative. In contrast to other amines, the 2-aminopyrrole precursors (13a-d) also exhibited potent activity against CMV. Unfortunately, most of these compounds displayed significant cytotoxicity against human fibroblasts, the cells supporting CMV and VZV replication, and thus selectivity indices were low. The most notable exception to this was the naphthyl-substituted aminopyrrole 13d, which exhibited both potent (IC(50)=0.3 microg/mL) and selective (CC(50)=>50 microg/mL) activity against CMV. Finally, thiophene aryl amides 8i-k displayed moderate in vitro activity against certain leukemia, breast, and colon cancer cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11377170     DOI: 10.1016/s0968-0896(00)00333-3

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  1-(4-Fluoro-phen-yl)-2-(phenyl-sulfon-yl)ethanone.

Authors:  Hatem A Abdel-Aziz; Hazem A Ghabbour; Suchada Chantrapromma; Hoong-Kun Fun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-05-05

2.  Atom-economic generation of gold carbenes: gold-catalyzed formal [3+2] cycloaddition between ynamides and isoxazoles.

Authors:  Ai-Hua Zhou; Qiao He; Chao Shu; Yong-Fei Yu; Shuang Liu; Tian Zhao; Wei Zhang; Xin Lu; Long-Wu Ye
Journal:  Chem Sci       Date:  2014-11-12       Impact factor: 9.825

3.  Electrochemical study of 4-chloroaniline in a water/acetonitrile mixture. A new method for the synthesis of 4-chloro-2-(phenylsulfonyl)aniline and N-(4-chlorophenyl)benzenesulfonamide.

Authors:  Niloofar Mohamadighader; Mahnaz Saraei; Davood Nematollahi; Hamed Goljani
Journal:  RSC Adv       Date:  2020-08-26       Impact factor: 4.036

4.  (Z)-1-(4-Methyl-phen-yl)-2-(phenyl-sulfon-yl)ethanone oxime.

Authors:  Hoong-Kun Fun; Tze Shyang Chia; Khalid A Al-Rashood; Hatem A Abdel-Aziz
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-07-07

5.  An efficient synthesis of N-substituted 3-nitrothiophen-2-amines.

Authors:  Sundaravel Vivek Kumar; Shanmugam Muthusubramanian; J Carlos Menéndez; Subbu Perumal
Journal:  Beilstein J Org Chem       Date:  2015-09-22       Impact factor: 2.883

Review 6.  Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Valeria Famiglini; Romano Silvestri
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

7.  Discovery of New Apoptosis-Inducing Agents for Breast Cancer Based on Ethyl 2-Amino-4,5,6,7-Tetra Hydrobenzo[b]Thiophene-3-Carboxylate: Synthesis, In Vitro, and In Vivo Activity Evaluation.

Authors:  Emad M Gad; Mohamed S Nafie; Elsayed H Eltamany; Magdy S A G Hammad; Assem Barakat; Ahmed T A Boraei
Journal:  Molecules       Date:  2020-05-28       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.